+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: A novel potential therapeutic target



Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: A novel potential therapeutic target



Cancer Letters 370(2): 313-323



Renal cell carcinoma (RCC) is the most lethal urologic malignancy; however, the molecular events supporting RCC carcinogenesis and progression remain poorly understood. In this study, based on the analysis of gene expression profile data from human clear cell RCC (ccRCC) and the corresponding normal tissues, we discovered that Hedgehog (HH) pathway component genes GLI1 and GLI2 were significantly elevated in ccRCC. Survival analysis of a large cohort of ccRCC samples demonstrated that the expression of GLI1 and GLI2 was negatively correlated with patient overall survival. Clinical sample-based VHL mutation and cell model-based VHL manipulation studies all indicated that the activation of GLI1 and GLI2 was not affected by VHL status. Further signaling pathway dissections demonstrated that GLI1 and GLI2 were activated by the phosphoinositide 3-kinase (PI3K)/AKT pathway, but not mediated by the canonical HH/SMO/GLI signaling. Up-regulation of GLI1 and GLI2 promoted RCC proliferation and clonogenic ability, whereas, a combination of GLIs inhibitor Gant61 and AKT inhibitor Perifosine synergistically suppressed RCC growth and induced apoptosis in vitro and in vivo. Therefore, this study identifies that GLI1 and GLI2 are critical for RCC carcinogenesis, and also provides an alternative therapeutic strategy for RCC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058414369

Download citation: RISBibTeXText

PMID: 26577809

DOI: 10.1016/j.canlet.2015.11.006


Related references

Pd33-12 Aberrant Activation Of Gli1/2 Via The Phosphoinositide 3-Kinase/Akt Pathway And Its Therapeutic Value In Clear-Cell Renal Cell Carcinoma. The Journal of Urology 193(4): e713-e714, 2015

Notch1 activation promotes renal cell carcinoma growth via PI3K/Akt signaling. Cancer Science 103(7): 1253-1258, 2012

The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clinical Cancer Research 16(24): 6060-6070, 2010

Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Research 66(4): 2328-2337, 2006

Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy. Oncotarget 8(24): 38755-38766, 2017

A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Science Translational Medicine 3(85): 85ra47, 2011

CCL2 as a potential therapeutic target for clear cell renal cell carcinoma. Cancer Medicine 5(10): 2920-2933, 2016

C-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Annals of Oncology 24(2): 343-349, 2013

Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clinical Cancer Research 13(19): 5703-5709, 2007

TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. Urologic Oncology 35(5): 286-293, 2017

MN/CA IX as a potential therapeutic target for active specific immunotherapy of renal cell carcinoma. European Urology 37(Suppl 2): 151, 2000

TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma. Lung Cancer 79(3): 205-214, 2013

Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Clinical Cancer Research 18(2): 380-391, 2012

AMP-activated protein kinase (AMPK) as a potential therapeutic target independent of PI3K/Akt signaling in prostate cancer. Oncoscience 1(6): 446-456, 2014

Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro. Cancer Medicine 7(8): 3955-3964, 2018